Stock Events

Stock Events

EV Biologics 

$0.000100
6
-$0.00-66.67%Wednesday 20:00

Statistics

Day High
0.0191
Day Low
0.0191
52W High
0.1056
52W Low
0.0001
Volume
10,000
Avg. Volume
876
Mkt Cap
1,022.5
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Aug 30Expected
Q1 2016
Q3 2016
Q4 2016
Q1 2017
Q2 2017
Q3 2017
Q2 2018
-25.59
-16.71
-7.82
1.06
Expected EPS
0
Actual EPS
-0.93

Financials

-167.98%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
178,000Revenue
-299,000Net Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that could compete with EV Biologics' regenerative medicine technologies.
Editas Medicine
EDIT
Mkt Cap410.06M
Editas Medicine operates in the genome editing field, directly competing with EV Biologics in developing treatments for genetic diseases.
Intellia Therapeutics
NTLA
Mkt Cap1.75B
Intellia Therapeutics is another key player in the CRISPR/Cas9 technology space, posing competition to EV Biologics in the genetic editing arena.
Beam Therapeutics
BEAM
Mkt Cap2.81B
Beam Therapeutics uses base editing, a form of gene editing, challenging EV Biologics in the precision genetic medicine field.
Voyager Therapeutics
VYGR
Mkt Cap105.98M
Voyager Therapeutics is involved in developing gene therapies, which could compete with EV Biologics' approach to treating diseases.
Fate Therapeutics
FATE
Mkt Cap249.23M
Fate Therapeutics is engaged in the development of programmed cellular immunotherapies, competing with EV Biologics in the cell therapy space.
Pacific Biosciences of California
PACB
Mkt Cap809.71M
Pacific Biosciences offers sequencing technologies that could complement or compete with EV Biologics' biotechnological research and development efforts.

About

EV Biologics, Inc. is a biotechnology enterprise focused on the commercial advancement of extracellular vesicles (EVs), utilizing them as biological agents for diagnostic and therapeutic applications. The company capitalizes on its proprietary, versatile EV platform to engineer innovative vaccines, treatments, and potential cures. Beyond EVs, it also dedicates efforts to cultivating human mesenchymal and other stem cells, as well as various cell-derived products, to address the needs of the cosmetic and biopharmaceutical industries. Founded in 2011, the firm was originally known as Yulong Eco-Materials Limited until its rebranding to EV Biologics, Inc. in August 2020, and it operates from its headquarters in Cheyenne, Wyoming.
Show More
CEO
Daniel S. McKinney
Employees
284
Country
United States
ISIN
US9884971030

Listings

OTC Link
US
YECO

0 Comments

Share your thoughts

FAQs

What is EV Biologics stock price today?▼
The current price of YECO is $0.00 USD — it has decreased by -66.67% in the past 24 hours. Watch EV Biologics stock price performance more closely on the chart.
What is EV Biologics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange EV Biologics stocks are traded under the ticker YECO.
Is EV Biologics stock price growing?▼
YECO stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year EV Biologics has showed a -99.9% decrease.
What is EV Biologics market cap?▼
Today EV Biologics has the market capitalization of 1,022.5
What were EV Biologics earnings last quarter?▼
YECO earnings for the last quarter are -0.93 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is EV Biologics revenue for the last year?▼
EV Biologics revenue for the last year amounts to 178,000 USD.
What is EV Biologics net income for the last year?▼
YECO net income for the last year is -299,000 USD.
How many employees does EV Biologics have?▼
As of November 2, 2026, the company has 284 employees.
In which sector is EV Biologics located?▼
EV Biologics operates in the Health & Wellness sector.
When did EV Biologics complete a stock split?▼
The last stock split for EV Biologics was on November 9, 2017 with a ratio of 1:5.
Where is EV Biologics headquartered?▼
EV Biologics is headquartered in Cheyenne, United States.